XTL Biopharmaceuticals Ltd - Asset Resilience Ratio

Latest as of December 2024: 9.03%

XTL Biopharmaceuticals Ltd (XTLB) has an Asset Resilience Ratio of 9.03% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See XTLB net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

ILA772.00K

≈ $2.07K USD Cash + Short-term Investments

Total Assets

ILA8.55 Million

≈ $22.92K USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2024)

This chart shows how XTL Biopharmaceuticals Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see XTL Biopharmaceuticals Ltd balance sheet assets.

Liquid Assets Composition Over Time

This chart breaks down XTL Biopharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of XTL Biopharmaceuticals Ltd to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	ILA0.00	0%
Short-term Investments	ILA772.00K	9.03%
Total Liquid Assets	ILA772.00K	9.03%

Asset Resilience Insights

Limited Liquidity: XTL Biopharmaceuticals Ltd maintains only 9.03% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

XTL Biopharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare XTL Biopharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for XTL Biopharmaceuticals Ltd (2013–2024)

The table below shows the annual Asset Resilience Ratio data for XTL Biopharmaceuticals Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	9.03%	ILA772.00K ≈ $2.07K	ILA8.55 Million ≈ $22.92K	-15.91pp
2023-12-31	24.94%	ILA605.00K ≈ $1.62K	ILA2.43 Million ≈ $6.50K	-13.93pp
2022-12-31	38.87%	ILA1.63 Million ≈ $4.36K	ILA4.19 Million ≈ $11.22K	-8.85pp
2021-12-31	47.72%	ILA3.16 Million ≈ $8.47K	ILA6.62 Million ≈ $17.74K	+10.64pp
2020-12-31	37.08%	ILA2.41 Million ≈ $6.46K	ILA6.50 Million ≈ $17.43K	+5.56pp
2019-12-31	31.52%	ILA2.27 Million ≈ $6.09K	ILA7.21 Million ≈ $19.34K	+7.96pp
2018-12-31	23.56%	ILA2.02 Million ≈ $5.42K	ILA8.57 Million ≈ $22.99K	-14.51pp
2017-12-31	38.07%	ILA2.51 Million ≈ $6.72K	ILA6.59 Million ≈ $17.66K	+24.34pp
2016-12-31	13.72%	ILA414.00K ≈ $1.11K	ILA3.02 Million ≈ $8.09K	+9.01pp
2015-12-31	4.72%	ILA251.00K ≈ $672.92	ILA5.32 Million ≈ $14.27K	-11.23pp
2013-12-31	15.95%	ILA1.28 Million ≈ $3.43K	ILA8.02 Million ≈ $21.49K	--

pp = percentage points

About XTL Biopharmaceuticals Ltd

TA:XTLB Israel Biotechnology

Market Cap

$4.25 Million

ILA1.59 Billion ILA

Market Cap Rank

#28992 Global

#419 in Israel

Share Price

ILA1.80

Change (1 day)

+0.00%

52-Week Range

ILA1.60 - ILA8.70

All Time High

ILA14.98